Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma

Neha Korde; Mark Roschewski; Adriana Zingone; Mary Kwok; Elisabet E. Manasanch; Manisha Bhutani; Nishant Tageja; Dickran Kazandjian; Sham Mailankody; Peter Wu; Candis Morrison; Rene Costello; Yong Zhang; Debra Burton; Marcia Mulquin; Diamond Zuchlinski; Liz Lamping; Ashley Carpenter; Yvonne Wall; George Carter; Schuyler C. Cunningham; Verena Gounden; Tristan M. Sissung; Cody J. Peer; Irina Marić; Katherine R. Calvo; Raul C. Braylan; Constance M. Yuan; Maryalice Stetler‐Stevenson; Diane C. Arthur; Katherine A. Kong; Li Weng; Malek Faham; Liza Lindenberg; Karen Kurdziel; Peter L. Choyke; Seth M. Steinberg; William D. Figg; Ola Landgren

doi:10.1001/jamaoncol.2015.2010

Abstract

Carfilzomib-lenalidomide-dexamethasone therapy is tolerable and demonstrates high rates of MRD negativity in NDMM, translating into longer progression-free survival in patients achieving MRD negativity. Carfilzomib-lenalidomide-dexamethasone therapy also demonstrates efficacy in high-risk SMM.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Korde et al. (2015) studied this question.

synapsesocial.com/papers/69dd61830644c7b49d40d47a https://doi.org/10.1001/jamaoncol.2015.2010

View Full Paper

Ask AI

Bookmark

Share

Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma

Abstract

Discussion

Cite This Study

Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma

Abstract

Discussion

Cite This Study

Keep reading

More from JAMA Oncology

Keep reading

More from JAMA Oncology